Related Experiment Video
Updated: Sep 28, 2025
Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones
Published on: February 5, 2018
Pharmacological characterization of 3,4-methylenedioxyamphetamine (MDA) analogs and two amphetamine-based compounds:
Karolina E Kolaczynska1, Paula Ducret1, Daniel Trachsel2
1Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Abstract:
3,4-methylenedioxyamphetamine (MDA) is a psychoactive compound chemically related to the entactogen MDMA. MDA shares some of the entactogenic effects of MDMA but also exerts stimulant effects and psychedelic properties at higher doses. Here, we examined the pharmacological properties of MDA analogs and related amphetamine-based compounds detected in street drug samples or in sport supplements. We examined the key pharmacological mechanisms including monoamine uptake inhibition and release using human embryonic kidney 293 cells stably transfected with the respective human transporters. Additionally, we assessed monoamine transporter and receptor binding and activation properties. MDA, its fluorinated analogs, as well as the α-ethyl containing BDB and the dimeric amphetamine DPIA inhibited NET with the greatest potency and preferentially inhibited 5-HT vs. dopamine uptake. The β‑methoxy MDA analog 3C-BOH and the amphetamine-based N,α-DEPEA inhibited NET and preferentially inhibited dopamine vs. 5-HT uptake. The test drugs mediated efflux of at least one monoamine with the exception of DPIA. Most compounds bound to 5-HT2A and 5-HT2C receptors (Ki ≤ 10 µM) and several substances activated the 5-HT2A and 5-HT2B receptor as partial or full agonists. Furthermore, several compounds interacted with adrenergic receptors and the trace amine-associated receptor 1 (TAAR1) in the micromolar range. The pharmacological profiles of some fluorinated and nonfluorinated MDA analogs resemble the profile of MDMA. In contrast, 3C-BOH and N,α-DEPEA displayed more pronounced dopaminergic activity similar to amphetamine. Pharmacokinetics and pharmacodynamics studies are necessary to better establish the risks and therapeutic potential of the tested drugs.
Insights
This study investigated the pharmacological effects of 3,4-methylenedioxyamphetamine (MDA) analogs and related amphetamines. Some analogs mimicked MDMA, while others showed amphetamine-like dopaminergic activity, highlighting varied risks and potential uses.
Area of Science:
- Pharmacology
- Neuroscience
- Medicinal Chemistry
Background:
- 3,4-methylenedioxyamphetamine (MDA) is a psychoactive substance related to MDMA, exhibiting entactogenic, stimulant, and psychedelic effects.
- The increasing prevalence of MDA analogs and related amphetamines in illicit and supplement markets necessitates a thorough understanding of their pharmacological profiles.
Purpose of the Study:
- To characterize the pharmacological properties of MDA analogs and related amphetamine-based compounds.
- To investigate their mechanisms of action, including monoamine transporter interactions and receptor binding/activation.
Main Methods:
- Utilized human embryonic kidney 293 cells expressing human monoamine transporters to assess uptake inhibition and release.
- Conducted binding and activation assays for monoamine transporters and various receptors, including serotonin and adrenergic receptors.
- Analyzed compounds found in street drugs and sport supplements.
Main Results:
- MDA analogs and related compounds demonstrated potent inhibition of norepinephrine transporter (NET) and preferential serotonin (5-HT) or dopamine uptake inhibition.
- Most tested drugs induced monoamine efflux, with exceptions noted.
- Several compounds bound to and activated 5-HT2A/2C receptors, with some acting as agonists.
- Some analogs exhibited significant dopaminergic activity, similar to amphetamine, while others resembled MDMA's profile.
Conclusions:
- The pharmacological profiles of MDA analogs vary, with some mirroring MDMA and others displaying amphetamine-like dopaminergic effects.
- Further pharmacokinetic and pharmacodynamic studies are crucial for assessing the risks and therapeutic potential of these compounds.
- Understanding these profiles is vital for public health and harm reduction strategies.
Related Concept Videos
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
01:30Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
01:29Drugs Affecting Neurotransmitter Synthesis